The Future of Downstream Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Future of Downstream Processing
The author reviews the state of downstream processing and considers potential solutions, including the streamlining of full processes and borrowed technologies.


Pharmaceutical Technology
Volume 35, pp. s36-s41

References

1. U. Gottschalk, "The Renaissance in Protein Purification" supplement to Biopharm. Intl. 19, 8–9 (2006).

2. D.L. Hacker, M. De Jesus, and F.M. Wurm, Biotechnol. Adv. 27, 1023–1027 (2009).

3. A.S. Rathore and H. Winkle, Nat. Biotechnol. 27, 26–34 (2009).

4. W. Berthold, Proceedings of BioManufacturing World 2010 (Shanghai, China, 2010).

5. F.M. Wurm, Nature 22, 1393–1398 (2004).

6. S. Aldridge, GEN, 26 (1) (2006).

7. FDA, "Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach" (Rockville, MD, August 2002).

8. FDA, "PAT Guidance for Industry: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance" (Rockville, MD, September 2004).

9. K.A. Thiel, Nat. Biotechnol 22, 1365–1372 (2004).

10. C. Sheridan, Nat. Biotechnol. 28, 307–310 (2010).

11. G. Walsh, Nat. Biotechnol. 28, 917–924 (2010).

12. U. Gottschalk, "New and Unknown Challenges Facing Biomanufacturing," supplement to BioPharm. Intl. 18 (3), 24–28 (2005).

13. S. Vunnum, G. Vedantham, and B. Hubbard (2009) "Protein A-based Affinity Chromatography," in Process Scale Purification of Antibodies, U. Gottschalk, Ed. (Wiley, NY, 2009) pp. 79–102.

14. J. Glynn et al., "The Development and Application of a Monoclonal Antibody Purification Platform," supplement to Biopharm. Intl. (2009).

15. J. Glynn et al., "Development of a MAb harvest protocol. Biochemical Engineering XV: Engineering Biology from Biomolecules to Complex Systems" (Quebec City, Canada, July 15-19 2007).

16. J. Thömmes and M. Etzel, Biotechnol. Prog. 23:42-45(2007)

17. J. Thömmes and U. Gottschalk, "Alternatives to Packed-bed Chromatography for Antibody Extraction and Purification," in Process-scale Purification of Antibodies, U. Gottschalk, Ed. (Wiley, NY, 2009) pp. 293–308.

18. A.A. Shulka and J.R. Kandula, "Harvest and recovery of monoclonal antibodies: Cell Removal and Clarification" in Process Scale Purification of Antibodies, U. Gottschalk, Ed. (Wiley, NY 2009 ) pp. 53–78.

19. R. Shpritzer et al., 232nd ACS National Meeting (San Francisco CA, 2006).

20. J. Glynn, "Process Scale Precipitation of Impurities in Mammalian Cell Culture Broth," in Process Scale Purification of Antibodies,U. Gottschalk, Ed. (Wiley, NY, 2009) pp. 309–324.

21. T. Przybycien, S. Narahari, and L. Steele, Biotechnol. 15, 469–478 (2004).

22. U. Kent, Methods in Molec. Biol. 115, 11–18 (1999).

23. M. Page and R. Thorpe, "Purification of IgG by Precipitation with Sodium Sulfate or Ammonium Sulfate," in The Protein Protocols Handbook, 2nd edition, J.M. Walker, Ed. (Humana Press, Totowa, NJ, 2002) pp. 983–984.

24. W. Lebing et al., Vox Sanguinis 84, 193–201(2003).

25. J. Parkkinen et al.,Vox Sanguinis 90, 97–104(2006).

26. V. Klyushnichenko, Curr. Opin. Drug. Disc. Dev. 6, 848–854 (2003).

27. M.X. Yang et al., Proc. Natl. Acad. Sci. USA, 100, 6934–6939. (2003).

28. J. Peters, T. Minuth, and W. Schröder, Protein Expr. Purif. 39, 43–53. (2005).

29. J. Curling and U. Gottschalk., BioPharm. Intl. 21, 70–94 (2007)

30. U. Gottschalk, Adv. Biochem. Eng. Biotechnol. 115, 171-183 (2010)

31. J.K. Walter et al., "Membrane separations," in Protein Purification: Principles, High Resolution Methods, and Applications, 3rd Edition, J.C. Janson, Ed. (Wiley, NY, in press, 2011)

32. U. Gottschalk, Biotechnol. Prog. 24, 496-503(2008).

33. J. Zhou and T. Tressel, Biotechnol. Prog. 22, 341–349(2006).

34. J. Thömmes and M.R. Kula, Biotechnol. Prog. 11, 357–367 (1995).

35. N. Fraud et al., BioPharm. Intl. 23, 24–27. (2009).

36. R. Faber, Y. Yang, and U. Gottschalk, BioPharm. Intl. 23, 11–14. (2009).

37. L. Giovannoni, M. Ventani, and U. Gottschalk, BioPharm. Intl. 23 (3) (2009).

38. S. Curtis et al., Biotechnol. Bioeng. 84, 179–186 (2003).

39. L. Norling, J. Chromatogr. 1069, 79–89 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here